Antibiotic Coverage for Hospitalized Patients with Tracheostomy and S. aureus Pneumonia

Risk Assessment and Initial Approach

The presence of a tracheostomy is a significant risk factor for healthcare-associated pneumonia with potential MRSA infection, according to the Infectious Diseases Society of America (IDSA) guidelines 1, 3
Without sensitivity results, all S. aureus isolates in hospitalized patients with tracheostomy should be treated as potential MRSA until proven otherwise, as recommended by the IDSA 1, 2
Patients with tracheostomy are considered at higher risk for mortality due to respiratory compromise, warranting aggressive initial coverage, with a strength of evidence considered low-quality but with a strong recommendation 2, 4

The IDSA recommends vancomycin as a first-line agent for MRSA pneumonia, with a dosing regimen of 15 mg/kg IV q8-12h and goal trough levels of 15-20 mg/mL, with a strength of evidence considered low-quality but with a strong recommendation 1, 5
Alternatively, linezolid is also recommended as a first-line agent for MRSA pneumonia, with a dosing regimen of 600 mg IV q12h, with a strength of evidence considered low-quality but with a strong recommendation 1, 5
For gram-negative coverage, the IDSA recommends one of the following antipseudomonal agents: piperacillin-tazobactam, cefepime, meropenem, or imipenem, due to the hospital setting and tracheostomy, with a strength of evidence considered moderate 1, 4

The IDSA/ATS guidelines recommend empiric MRSA coverage for patients with prior hospitalization, presence of invasive devices (like tracheostomy), and healthcare exposure, with a strength of evidence considered high 1, 3
Vancomycin and linezolid are specifically recommended as first-line agents for MRSA pneumonia, with a strength of evidence considered low-quality but with a strong recommendation 1

Once sensitivity results become available, therapy should be narrowed: if MSSA, switch to oxacillin, nafcillin, or cefazolin, with a strength of evidence considered high 4, 6
If MRSA, continue vancomycin or linezolid based on clinical response, with a strength of evidence considered low-quality but with a strong recommendation 1

Monitor vancomycin trough levels if used, with a target of 15-20 mg/mL, with a strength of evidence considered moderate 5
Reassess clinical response within 48-72 hours, with a strength of evidence considered moderate 1
Obtain follow-up cultures if patient fails to improve, with a strength of evidence considered moderate 3
Standard duration for S. aureus pneumonia is 7-14 days, based on clinical response, with a strength of evidence considered moderate 1, 3